Family Medicine & Primary Care Review
eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
2/2025
vol. 27
 
Share:
Send email
Share:
Original paper

Semaglutide in modern medicine: therapeutic opportunities in obesity and the emerging challenge of NAION – a narrative review

Kamil Biedka
1
,
Michał Wesołowski
1
,
Oliwia Ziobro
1
,
Katarzyna Błaszczyk
1
,
Jakub Bulski
2
,
Aleksandra Ewa Sobaś
2
,
Filip Jacek Maj
2
,
Anna Maria Klasa
3
,
Karol Bartłomiej Sornat
2
,
Agata Estreicher
1
,
Emilia Majewska
4

  1. Department of Physiology and Pathophysiology, Division of Pathophysiology, Wroclaw Medical University, Wroclaw, Poland
  2. Collegium Medicum, Jan Kochanowski University, Kielce, Poland
  3. University Hospital in Cracow, Cracow, Poland
  4. Department of Internal Medicine, Specialist Hospital in Radom, Radom, Poland
Family Medicine & Primary Care Review 2025; 27(2): 215–221
DOI: https://doi.org/10.5114/fmpcr.2025.150180
Online publish date: 2025/06/27
Article file
- 13 FM&PCR 2 25 - R - Biedka - 1768 - Semaglutide.pdf  [0.30 MB]
Get citation
 
PlumX metrics:
 
1. Obesity and overweight [cited 25.11.2024]. Available from URL: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
2. WHO European Regional Obesity Report 2022 [cited 25.11.2024]. Available from URL: http://apps.who.int/bookorders.
3. Haththotuwa RN, Wijeyaratne CN, Senarath U. Worldwide epidemic of obesity. In: Mahmood TA, Arulkumaran S, Chervenak FA, eds. Obesity and Obstetrics. 2nd ed. Elsevier; 2020: 3–8.
4. Velazquez A, Apovian CM. The Effects of Obesity on Health Care Delivery. Gastroenterol Clin North Am 2023; 52: 381–392.
5. Gryszkiewicz P, Szydło J, Starownik J, et al. Review of upcoming and currently available anti-obesity drugs in Europe. J Educ Health Sport 2023; 30: 57–67.
6. Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab 2021; 46: 101102.
7. Koliaki C, Doupis J. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther 2011; 2(2): 101–121.
8. Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131–2157.
9. Sanz C, Blázquez E. New gene targets for glucagon-like peptide-1 during embryonic development and in undifferenti-ated pluripotent cells. Am J Physiol Endocrinol Metab 2011; 301(3): E494–E503, doi: 10.1152/ajpendo.00116.2011.
10. Chao AM, Tronieri JS, Amaro A, et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med 2023; 33: 159–166.
11. Christoffersen BØ, Sanchez-Delgado G, John LM, et al. Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. Obesity 2022; 30: 841–857.
12. Delgado-Aros S, Kim DY, Burton DD, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 2002; 282(3): G424–G31.
13. Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord 2014; 15: 181.
14. Turton MD, O’Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69–72.
15. McLean BA, Wong CK, Campbell JE, et al. Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Recep-tor Activation. Endocr Rev 2021; 42(2): 101–132.
16. Bloemendaal L, van, Ten Kulve JS, La Fleur SE, et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 2014; 221(1): T1–T16.
17. Armstrong M, Hull D, Guo K, et al. Effect of liraglutide on adipose insulin resistance and hepatic de-novo lipogenesis in non-alcoholic steatohepatitis: substudy of a phase 2, randomised placebo-controlled trial. Lancet 2014; 383: S21.
18. Petrovic A, Igrec D, Rozac K, et al. The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD. Curr Issues Mol Biol 2023; 45: 4544.
19. Ozempic. European Medicines Agency (EMA) [cited 24.11.2024]. Available from URL: https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic.
20. Rodbard HW, Lingvay I, Reed J, et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. J Clin Endocrinol Metab 2018; 103: 2291–2301.
21. Suran M. As Ozempic’s Popularity Soars, Here’s What to Know About Semaglutide and Weight Loss. JAMA 2023; 329: 1627–1629.
22. Mailhac A, Pedersen L, Pottegård A, et al. Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss. Clin Epidemiol 2024; 16: 307–318.
23. Rybelsus. European Medicines Agency (EMA) [cited 24.11.2024]. Available from URL: https://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus.
24. Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of Oral Semaglutide Compared with Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients with Type 2 Diabetes: A Randomized Clinical Trial. JAMA 2017; 318: 1460–1470.
25. Wegovy. European Medicines Agency (EMA) [cited 24.11.2024]. Available from URL: https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy.
26. Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med 2024; 30: 2049–2057.
27. Ghusn W, De La Rosa A, Sacoto D, et al. Weight Loss Outcomes Associated with Semaglutide Treatment for Patients with Overweight or Obesity. JAMA Netw Open 2022; 5: e2231982.
28. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384: 989–1002.
29. Lingvay I, Deanfield J, Kahn SE, et al. Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People with Overweight or Obesity but Without Diabetes in SELECT. Diabetes Care 2024; 47: 1360–1369.
30. Noncommunicable diseases: Childhood overweight and obesity [cited 26.12.2024]. Available from URL: https://www.who.int/news-room/questions-and-answers/item/noncommunicable-diseases-childhood-overweight-and-obesity.
31. Simmonds M, Llewellyn A, Owen CG, et al. Predicting adult obesity from childhood obesity: a systematic review and meta-analysis. Obes Rev 2016; 17: 95–107.
32. Vajravelu ME, Tas E, Arslanian S. Pediatric Obesity: Complications and Current Day Management. Life 2023; 13: 1591.
33. Bensignor MO, Kelly AS, Arslanian S. Anti-obesity pharmacotherapy for treatment of pediatric type 2 diabetes: Re-view of the literature and lessons learned from adults. Front Endocrinol 2022; 13: 1043650.
34. Kelly AS, Arslanian S, Hesse D, et al. Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg. Obesity 2023; 31: 2139–2149.
35. Luo Z-Y, Li X, Chen C-T, et al. Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology. Expert Opin Drug Saf 2025; 24(3): 287–296.
36. Singh AK, Kesavadev J, Tiwaskar M. Nonarteritic Anterior Ischemic Optic Neuropathy and Semaglutide: What is This All About? J Assoc Physicians India 2024; 72: 11–12.
37. Mesentier-Louro LA, Liao YJ. Optic Nerve Regeneration: Considerations on Treatment of Acute Optic Neuropathy and End-Stage Disease. Curr Ophthalmol Rep 2019; 7: 11–20.
38. Foroozan R. New Treatments for Nonarteritic Anterior Ischemic Optic Neuropathy. Neurol Clin 2017; 35: 1–15.
39. Bernstein SL, Miller NR. Ischemic optic neuropathies and their models: disease comparisons, model strengths and weaknesses. Jpn J Ophthalmol 2015; 59: 135–147.
40. Bialer OY, Stiebel-Kalish H. Evaluation and management of nonarteritic anterior ischemic optic neuropathy: a national survey. Graefes Arch Clin Exp Ophthalmol 2024; 262: 3330.
41. Park GT, Galetta S. Distinguishing Between Myelin Oligodendrocyte Glycoprotein Disease Optic Neuritis and Nonarteritic Anterior Ischemic Optic Neuropathy. Neurol Neuroimmunol Neuroinflamma 2024; 11(3): e200240.
42. Biousse V, Newman NJ. Ischemic Optic Neuropathies. N Engl J Med 2015; 372: 2428–2436.
43. Beyer TR, Oterendorp C, van. Nonarteritic anterior ischemic optic neuropathy (NAION). Ophthalmologie 2023; 120: 1159–1169.
44. Allegrini D, Pagano L, Ferrara M, et al. Optic disc drusen: a systematic review. Int Ophthalmol 2020; 40: 2119–2127.
45. Hayreh SS. Ischaemic optic neuropathy. Indian J Ophthalmol 2000; 48: 171–194.
46. Bernstein SL, Johnson MA, Miller NR. Nonarteritic anterior ischemic optic neuropathy (NAION) and its experimental models. Prog Retin Eye Res 2011; 30: 167–187.
47. Hayreh SS. Ocular vascular occlusive disorders: Natural history of visual outcome. Prog Retin Eye Res 2014; 41: 1–25.
48. Grauslund J, Taha AA, Molander LD, et al. Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous 2024; 10: 97.
49. Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol 2024; 142: 732–739.
50. Simonsen E, Lund LC, Ernst MT, et al. Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish–Norwegian cohort study. medRxiv 2024; 2024.12.09.24318574.
51. Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ 2024; 384: e076410.
52. Li A, Su X, Hu S, et al. Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract 2023; 198: 110605.
53. Li J, He K, Ge J, et al. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract 2021; 172: 108656.
54. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834–1844.
55. Gao X, Hua X, Wang X, et al. Efficacy and safety of semaglutide on weight loss in obese or overweight patients with-out diabetes: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2022; 13: 935823.
56. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083–2091.
57. Amaro A, Sugimoto D, Wharton S. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgrad Med 2022; 134: 5–17.
58. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med 2022; 387: 2245–2257.
Copyright: © 2025 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.